Virax Biolabs Group Ltd Experiences Significant Price Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: 424B5
Virax Biolabs Group Ltd's stock fell by 12.83%, crossing down the 5-day SMA amid a broader market decline.
The Nasdaq-100 and S&P 500 indices are down 0.10% and 0.20%, respectively, reflecting a general weakness in the market.
This decline may impact investor sentiment, especially as Virax continues to secure funding and advance its research initiatives.
Analyst Views on VRAX
Wall Street analysts forecast VRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRAX is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.290
Low
1.00
Averages
1.00
High
1.00
Current: 0.290
Low
1.00
Averages
1.00
High
1.00
About VRAX
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
